Despite a lack of published data, clinical trials have demonstrated most CH therapies to be repurposed from other neoplasms that share common molecular pathways, with an increased focus on small molecules (TKIs, EZH2 inhibitors) and combination therapeutics. This evidence concerns the gene EZH2 and cyclic hematopoiesis.